金币
UID204275
帖子
主题
积分723
注册时间2015-6-25
最后登录1970-1-1
听众
性别保密
|
发表于 2021-12-23 14:12:20
|
显示全部楼层
本帖最后由 lisu247 于 2021-12-23 14:13 编辑
很负责任的说,你没有认真细看Q3D
ICH Q3D 5.6 风险评估过程总结:
The risk assessment is summarized by reviewing relevant product or component specific data combined with information and knowledge gained across products or processes to identify the significant probable elemental impurities that may be observed in the drug product.
The summary should consider the significance of the observed or predicted level of the elemental impurity relative to the PDE of the elemental impurity. As a measure of the significance of the observed elemental impurity level, a control threshold is defined as a level that is 30% of the established PDE in the drug product. The control threshold may be used to determine if additional controls may be required.If the total elemental impurity level from all sources in the drug product is expected to be consistently less than 30% of the PDE, then additional controls are not required, provided the applicant has appropriately assessed the data and demonstrated adequate controls on elemental impurities.
风险评估的总结是通过综合相关药品或组分的特定数据,并结合从药品或制备工艺中获得的信息和认知,用以识别在药品中很可能观察到的元素杂质。
总结中应考虑实测的或预测的元素杂质水平相对于其PDE 值的显著性。将药品既定 PDE 值的 30%定义为控制阈值,作为实测元素杂质水平显著性的衡量指标。控制阈值可用于判断是否需要额外的控制。
如果药品中所有来源的总元素杂质水平始终低于 PDE的 30%,只要申请人对数据进行了适当的评估并证明已对元素杂质进行了足够的控制,则不再需要额外的控制。
|
|